New mRNA Vaccines for Tuberculosis
Development of Novel mRNA Vaccines Against Mycobacterium tuberculosis
This research explores new mRNA vaccine technology to protect adolescents and adults from tuberculosis, a serious lung infection.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | International AIDS Vaccine Initiative NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11325903 on NIH RePORTER |
What this research studies
Tuberculosis (TB) remains a major global health challenge, causing millions of illnesses and deaths each year, especially with the rise of drug-resistant forms and its connection to HIV. Current vaccine efforts often use similar approaches, so this project aims to bring fresh ideas and new technology to the field. Researchers are using advanced mRNA vaccine methods, similar to those used for COVID-19, to create a more diverse and effective vaccine. The goal is to develop a powerful new tool that could prevent people from getting, developing, and spreading TB.
Who could benefit from this research
Good fit: This preclinical research is focused on developing a vaccine that would ultimately benefit adolescents and adults, including those living with conditions like HIV that increase TB risk.
Not a fit: Patients will not receive direct benefit from this early-stage laboratory and animal model research, as it is not yet ready for human testing.
Why it matters
Potential benefit: If successful, this work could lead to a highly effective vaccine that prevents tuberculosis, including drug-resistant forms, and significantly reduces its global impact.
How similar studies have performed: While other TB vaccine candidates are in development, this project introduces novel mRNA technology and aims to broaden the range of immune responses, offering a new approach.
Where this research is happening
New York, United States
- International AIDS Vaccine Initiative — New York, United States (Active)
Researchers
- Principal investigator: Postler, Thomas Siegmund — International AIDS Vaccine Initiative
- Study coordinator: Postler, Thomas Siegmund
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.